By Research Area
Hot products 
-
Mouse Anti-H1-0 Recombinant Antibody (CBFYH-0565) (CBMAB-H1451-FY)
-
Human Anti-SARS-CoV-2 Spike Recombinant Antibody (CBC05) (CBMAB-CR005LY)
-
Mouse Anti-His tag Recombinant Antibody (12) (CBMAB-2108CQ)
-
Mouse Anti-2C TCR Recombinant Antibody (V2-1556) (CBMAB-0951-LY)
-
Mouse Anti-CDKL5 Recombinant Antibody (CBFYC-1629) (CBMAB-C1689-FY)
-
Mouse Anti-ACTG1 Recombinant Antibody (V2-179597) (CBMAB-A0916-YC)
-
Rabbit Anti-Acetyl-Histone H3 (Lys36) Recombinant Antibody (V2-623395) (CBMAB-CP0994-LY)
-
Mouse Anti-C1QC Recombinant Antibody (CBFYC-0600) (CBMAB-C0654-FY)
-
Mouse Anti-BHMT Recombinant Antibody (CBYY-0547) (CBMAB-0550-YY)
-
Mouse Anti-HTLV-1 gp46 Recombinant Antibody (CBMW-H1006) (CBMAB-V208-1154-FY)
-
Mouse Anti-ASTN1 Recombinant Antibody (H-9) (CBMAB-1154-CN)
-
Human Anti-SARS-CoV-2 S1 Monoclonal Antibody (CBFYR-0120) (CBMAB-R0120-FY)
-
Mouse Anti-FPR2 Recombinant Antibody (1D6) (CBMAB-F2628-CQ)
-
Mouse Anti-Gro Monoclonal Antibody (1) (CBMAB-0482-LY)
-
Mouse Anti-GLP1R Recombinant Antibody (4F3) (CBMAB-G0521-LY)
-
Mouse Anti-CD83 Recombinant Antibody (HB15) (CBMAB-C1765-CQ)
-
Mouse Anti-C5AR1 Recombinant Antibody (R63) (CBMAB-C9553-LY)
-
Human Anti-SARS-CoV-2 Spike Recombinant Antibody (CR3022) (CBMAB-CR014LY)
-
Mouse Anti-CD2AP Recombinant Antibody (BR083) (CBMAB-BR083LY)
-
Mouse Anti-FTH1 Recombinant Antibody (CBXF-1896) (CBMAB-F3426-CQ)
Lung Cancer Research
Lung cancer, formally known as primary bronchogenic carcinoma, originates from the epithelial cells of the bronchial mucosa or glands, which is one of the most prevalent malignancies worldwide. It is primarily classified into non-small cell lung cancer (NSCLC) and SCLC based on histopathological characteristics. While lung cancer is non-contagious, it exhibits significant familial clustering and genetic susceptibility. Common causes of lung cancer involve smoking, occupational exposure, and air pollution. According to the latest global cancer report released by the International Agency for Research on Cancer (IACR) in 2024, lung cancer ranks first in both new cases (12.4%) and deaths (18.7%), making it the leading cancer worldwide, particularly among men.
Discover our advanced antibody products, which will significantly enhance your work in lung cancer diagnosis and treatment research. These antibodies are carefully designed to possess high specificity and sensitivity, enabling accurate biomarker identification and assessment.
Please try the standard protocols which include: protocols, troubleshooting and guide.
Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols
Reference
- Lahiri, Aritraa, et al. "Lung cancer immunotherapy: progress, pitfalls, and promises." Molecular cancer 22.1 (2023): 40. Distributed under Open Access license CC BY 4.0. The image was modified by extracting and using only Part B of the original image.
